Fundraising Fox

Sun BioPharma

Waconia, US · Delaware corporation

Biotech

Founders & leadership

SK
SCOTT KELLENExecutive
DB
DAVID B. KAYSENExecutive
MT
MICHAEL T. CULLENNamed on SEC filing

Board

DS
DALVIR S. GILLBoard director
SG
SUZANNE GAGNONBoard director
JR
J. ROBERT PAULSONBoard director
DR
D. ROBERT SCHEMELBoard director
JS
JEFFREY S. MATHIESENBoard director
PW
PAUL W. SCHAFFERBoard director

Reported raises · per SEC filings

Form D private placements

$22.3M disclosed across 8 rounds · 2016–2023

▶$2MraisedJan 2024 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jennifer K. SimpsonExecutive Officer, Director
  • Daniel DonovanDirector
  • Jeffrey S. MathiesenDirector
  • Susan HorvathExecutive Officer
  • Arthur J. FratamicoDirector
  • Jeffrey E. JacobDirector
  • Michael T. CullenDirector
  • Robert SchemelDirector
Amount sold
$2M
Sales commissions
$120K
Placement agents
Roth Capital Partners, LLC
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.3MraisedNov 2023 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel DonovanDirector
  • Robert SchemelDirector
  • Michael T. CullenDirector
  • Jeffrey E. JacobDirector
  • Susan HorvathExecutive Officer
  • Jeffrey S. MathiesenDirector
  • Arthur J. FratamicoDirector
  • Jennifer K. SimpsonExecutive Officer, Director
Amount sold
$3.3M
Sales commissions
$114K
Placement agents
Roth Capital Partners, LLC
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.8MraisedJun 2022 · 70 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jennifer K. SimpsonExecutive Officer, Director
  • Michael T. CullenDirector
  • Jeffrey S. MathiesenDirector
  • Daniel DonovanDirector
  • Robert D. SchemelDirector
  • Susan HorvathExecutive Officer
  • Jeffrey E. JacobDirector
  • Arthur J. FratamicoDirector
Amount sold
$8.8M
First sale
Jun 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedSep 2019 · 38 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul W. SchafferDirector
  • Robert D. SchemelDirector
  • Susan M. HorvathExecutive Officer
  • Michael T. CullenExecutive Officer, Director
  • Jeffrey S. MathiesenDirector
  • Suzanne GagnonDirector
Amount sold
$2.5M
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.4MraisedJan 2019 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • SUSAN M. HORVATHExecutive Officer
  • JEFFREY S. MATHIESENDirector
  • PAUL W. SCHAFFERDirector
  • MICHAEL T. CULLENExecutive Officer, Director
  • SUZANNE GAGNONDirector
  • D. ROBERT SCHEMELDirector
  • J. ROBERT PAULSON, JR.Director
Offering amount
$2M
Amount sold
$1.4M
First sale
Dec 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$840KraisedMar 2018 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL T. CULLENExecutive Officer, Director
  • DAVID B. KAYSENExecutive Officer, Director
  • SUZANNE GAGNONDirector
  • D. ROBERT SCHEMELDirector
  • PAUL W. SCHAFFERDirector
  • J. ROBERT PAULSON, JR.Director
  • SCOTT KELLENExecutive Officer
  • JEFFREY S. MATHIESENDirector
  • DALVIR S. GILLDirector
Offering amount
$20M
Amount sold
$840K
First sale
Feb 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedMar 2017 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Suzanne GagnonDirector
  • Paul W SchafferDirector
  • David B KaysenExecutive Officer, Director
  • D. Robert SchemelDirector
  • Scott KellenExecutive Officer
  • Jeffrey S MathiesenDirector
  • Michael T CullenExecutive Officer, Director
  • J. Robert Paulson, Jr.Director
  • Dalvir S GillDirector
Offering amount
$5M
Amount sold
$1.5M
First sale
Feb 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJun 2016 · 27 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • DALVIR S. GILLDirector
  • SUZANNE GAGNONDirector
  • J. ROBERT PAULSONDirector
  • D. ROBERT SCHEMELDirector
  • MICHAEL T. CULLENExecutive Officer, Director
  • JEFFREY S. MATHIESENDirector
  • PAUL W. SCHAFFERDirector
  • SCOTT KELLENExecutive Officer
  • DAVID B. KAYSENExecutive Officer, Director
Offering amount
$5M
Amount sold
$2M
Finders' fees
$75K
Placement agents
LAKE STREET CAPITAL MARKETS, LLC, CHARDAN CAPITAL MARKETS LLC
First sale
Jun 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Sun BioPharma, Inc. announced that it expects to receive $5 million in funding | MarketScreenermarketscreener.com · Feb 2017Sun BioPharma, Inc. Raises $2.0 Million Through Private Placement Transactionglobenewswire.com · Jun 2016

Frequently asked questions

How much funding has Sun BioPharma raised?
Sun BioPharma has disclosed $22.3M raised across 8 rounds.
Where is Sun BioPharma headquartered?
Sun BioPharma is headquartered in Waconia, US.